• 1
    Prichard BNC. Hypotensive action of pronethalol. Br Med J. 1964;1:12271228.
  • 2
    Prichard BNC, Gillam PMS. Use of propranolol (Inderal) in the treatment of hypertension. Br Med J. 1964;2:725727.
  • 3
    Frishman WH. Alpha-and beta-adrenergic blocking drugs. In: Frishman WH, Sica DA, eds. Cardiovascular Pharmacotherapeutics, 3rd ed. Minneapolis, MN: Cardiotext Inc.; 2011:5786.
  • 4
    Frishman WH, Sica DA. β-Adrenergic blockers. In: Izzo JL Jr, Sica D, Black HR, eds. Hypertension Primer, 4th ed.: The Essentials of High Blood Pressure. Philadelphia, PA: Wolters Kluwer/Lippincott Williams & Wilkins; 2008:446450.
  • 5
    Mansoor GA, Frishman WH. Comprehensive management of hypertensive emergencies and urgencies. Heart Dis. 2002;4:358371.
  • 6
    Messerli F, Grossman E, Goldbourt U. Are beta blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review. JAMA. 1998;279:19031907.
  • 7
    Kaplan NM. Beta blockers in hypertension. Adding insult to injury (editorial comment). J Am Coll Cardiol. 2008;52:14901491.
  • 8
    MRC Working Party. Medical research council trial of treatment of hypertension in older adults: principal results. Br Med J. 1992;304:405412.
  • 9
    Lever AF, Brennan PJ. MRC trial of treatment in elderly hypertensives. Clin Exp Hypertens. 1993;15:941952.
  • 10
    Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA), a multicentre randomised controlled trial. Lancet. 2005;366:895906.
  • 11
    Aronow WS, Fleg JL, Pepine CJ, et al. ACCF/AHA 2010 Expert Consensus Document on Hypertension in the Elderly. A report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents, in collaboration with the American Academy of Neurology, Association of Black Cardiologists, American Geriatrics Society, American Society of Hypertension, American Society of Nephrology, American Society for Preventive Cardiology, and the European Society of Hypertension. J Am Coll Cardiol. 2011;57:20372114.
  • 12
    Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet. 2005;366:15451553.
  • 13
    Khan N, McAlister FA. Reexamining the efficacy of beta blockers for the treatment of hypertension: a meta analysis. CMAJ. 2006;174:17371742.
  • 14
    Williams B, Lacy PS, Thorn SM, et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFÉ) study. Circulation. 2006;113:12131225.
  • 15
    Frishman WH. A historical perspective on the development of β-adrenergic blockers. J Clin Hypertens. 2007;9(suppl 3):1927.
  • 16
    Frishman WH. Fifty years of beta-adrenergic blockade: a golden era in clinical medicine and molecular pharmacology (commentary). Am J Med. 2008;121:933934.
  • 17
    Saunders E, Smith WB, DeSalvo KB, et al. The efficacy and tolerability of nebivolol in hypertensive African American patients. J Clin Hypertens (Greenwich). 2007;9:866875.
  • 18
    Frishman WH, Schlocker SJ, Awad K, et al. Pathophysiology and medical management of systemic hypertension in pregnancy. Cardiol Rev. 2005;13:274284.
  • 19
    Frishman WH. β-Adrenergic blockers: a 50-year historical perspective. Am J Ther. 2008;15:565576.
  • 20
    Frishman WH. Drug therapy: pindolol: a new beta-adrenoceptor antagonist with partial agonist activity. N Engl J Med. 1983;308:940944.
  • 21
    Frishman WH. Carvedilol. N Engl J Med. 1998;339:17591765.
  • 22
    Sule SS, Frishman W. Nebivolol, a new therapy update. Cardiol Rev. 2006;14:259264.
  • 23
    Frishman WH, Furberg CD, Friedewald WT. Beta-adrenergic blockade for survivors of acute myocardial infarction. N Engl J Med. 1984;310:830837.
  • 24
    Klingbeil AU, Schneider M, Martus P, et al. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 2003;115:4146.
  • 25
    Ong KT, Perdu J, De Backer J, et al. Effect of celiprolol on prevention of cardiovascular events in vascular Ehlers–Danlos syndrome: a prospective randomised, open, blinded-endpoints trial. Lancet. 2010;376:14761484.
  • 26
    Harte B, Jaffer AK. Perioperative beta-blockers in noncardiac surgery: evolution of the evidence. Cleve Clin J Med. 2008;75:513519.
  • 27
    Mangano DT, Layug EL, Wallace A, et al. Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery Multicenter study of perioperative ischemia research group. N Engl J Med. 1996;335:17131720.
  • 28
    Poldermans D, Boersma E, Bax JJ, et al. The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography Study Group. N Engl J Med. 1999;341:17891794.
  • 29
    Shojania KG, Duncan BW, McDonald KM, et al. Making health care safer: a critical analysis of patient safety practices. Evid Rep Technol Assess (Summ). 2003;43:ix1–668.
  • 30
    National Quality Forum. Safe Practices for Better Healthcare – 2006 Update. Washington, DC: National Quality Forum; 2006.
  • 31
    Fleischmann KE, Beckman JA, Buller CE, et al. ACCF/AHA focused update on perioperative beta blockade. J Am Coll Cardiol. 2009;54:21022128.
  • 32
    POISE Study Group. Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE Trial): a randomized controlled trial. Lancet. 2008;371:18391847.
  • 33
    Bangalore S, Wetterslev J, Pranesh S, et al. Perioperative beta blockers in patients having non-cardiac surgery: a meta-analysis. Lancet. 2008;372:19621976.
  • 34
    Bangalore S, Parkar S, Grossman E, et al. A meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus. Am J Cardiol. 2007;8:12541262.
  • 35
    Messerli FH, Bangalore S. Antihypertensive efficacy of aliskiren: is hydrochlorothiazide an appropriate benchmark? Circulation. 2009;3:371373.
  • 36
    Bakris GL, Fonseca V, Katholi RE, et al. for the GEMINI Investigators: Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA. 2004;292:22272236.
  • 37
    Messerli FH, Bell DS, Fonseca V, et al. GEMINI Investigators. Body weight changes with beta-blocker use: results from GEMINI. Am J Med. 2007;120:610615.
  • 38
    Cheng-Lai A, Nawarskas J, Frishman WH. Cardiovascular drug interactions. In: Frishman WH, Sica DA, eds. Cardiovascular Pharmacotherapeutics, 3rd ed, Minneapolis, MN: Cardiotext Inc.; 2011: 493518.
  • 39
    Chobanian AV, Bakris GL, Black HR, et al. The Seventh report of the joint national committee on prevention, detection, evaluation and treatment of high blood pressure: the JNC-7 report. JAMA. 2003;289:25602572.
  • 40
    Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a European Society of hypertension task force document. J Hypertens. 2009;27:21212158.
  • 41
    Bangalore S, Sawhney S, Messerli FH. Relation of beta-blocker-induced heart rate lowering and cardioprotection in hypertension. J Am Coll Cardiol. 2008;52:14821489.
  • 42
    Frishman WH. Clinical Pharmacology of the β-Adrenoceptor Blocking Drug, 2nd ed. Norwalk, CT: Appleton-Century-Crofts; 1984.
  • 43
    Frishman WH. β-Adrenergic blockers. Med Clin North Am. 1988;72:3781.